Cong Claire Xu
CIK: 0002114309
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NovaBridge Biosciences
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Aug 31, 2026NBP
NovaBridge Biosciences
Sale(S)Direct3.3K shares at avg. $0.79$3K - Aug 30, 2026NBP
NovaBridge Biosciences
Exercise(M)Direct9.4K shares- - Jul 6, 2026NBP
NovaBridge Biosciences
Sale(S)Direct4.5K shares at avg. $0.89$4K - Jul 4, 2026NBP
NovaBridge Biosciences
Exercise(M)Direct12.4K shares- - Jun 1, 2026NBP
NovaBridge Biosciences
Sale(S)Direct3.5K shares at avg. $3.94$14K - May 30, 2026NBP
NovaBridge Biosciences
Exercise(M)Direct9.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 31, 2026 | NBP NovaBridge Biosciences | Sale(S) | 3,282 | $0.79 | $2,593 | Direct |
| Aug 30, 2026 | NBP NovaBridge Biosciences | Exercise(M) | 9,382 | - | $0 | Direct |
| Jul 6, 2026 | NBP NovaBridge Biosciences | Sale(S) | 4,485 | $0.89 | $3,992 | Direct |
| Jul 4, 2026 | NBP NovaBridge Biosciences | Exercise(M) | 12,432 | - | $0 | Direct |
| Jun 1, 2026 | NBP NovaBridge Biosciences | Sale(S) | 3,494 | $3.94 | $13,766 | Direct |
| May 30, 2026 | NBP NovaBridge Biosciences | Exercise(M) | 9,382 | - | $0 | Direct |
1-6 of 6 transactions
About Xu Cong Claire
Xu Cong Claire (SEC CIK 0002114309) files insider reports with the SEC as EVP, Clinical Development of NovaBridge Biosciences (NBP).
Signal8 holds 5 ownership filings by Xu Cong Claire (2 Form 3, 3 Form 4), filed between Mar 18, 2026 and Sep 1, 2026. Those filings report 6 transactions, from May 30, 2026 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Xu Cong Claire's filings is in ROCKVILLE, MD.
Recent filings by Xu Cong Claire
- Aug 31, 2026: Open-market sale of NBP shares (Form 4, code S).
- Aug 30, 2026: Option exercise of NBP shares (Form 4, code M).
- Jul 6, 2026: Open-market sale of NBP shares (Form 4, code S).
- Jul 4, 2026: Option exercise of NBP shares (Form 4, code M).
- Jun 1, 2026: Open-market sale of NBP shares (Form 4, code S).
Other insiders filing for NovaBridge Biosciences (NBP)
- Silberstein Charles, Chief Financial Officer
- Woo Ian Ying, Director
- Dennis Phillip Andrew, Chief Medical Officer
- Cao Sean Wuxiong, Chief Bus. Development Officer
- Dewhurst Martin William, Director
- Lenz Robert A., Director